Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest ...

In a notable update, Cantor Fitzgerald has reiterated its “Overweight” rating on Ascendis Pharma’s stock. The analyst’s price target remains set at $170, reflecting optimism about the company’s future ...

Ascendis Pharma A/S (NASDAQ:ASND) released topline data on Monday from a trial that included 84 children with achondroplasia, ...

(RTTNews) - Ascendis Pharma A/S (ASND) said that it has priced its underwritten public offering of 2 million American Depositary Shares or "ADSs" at $150.00 per ADS. Each ADS represents one ordinary ...

Shares of Ascendis Pharma ASND rose 17% on Monday after it reported top-line results from the pivotal ApproaCH study that ...

We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to ...

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by ...

Check the time stamp on this data. Updated AI-Generated Signals for Ascendis Pharma A/s (ASND) available here: ASND.

BioMarin Pharmaceutical Inc.'s stagnant shares present a compelling investment opportunity amid uncertainty in the ...

Analyst Paul Choi of Goldman Sachs maintained a Buy rating on Ascendis Pharma (ASND – Research Report), boosting the price target to ...

After its sold-out run at Brooklyn Academy of Music in winter 2024, the off-Broadway production Our Class, by Polish ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $190.00. The company’s shares closed yesterday at $139.57.